Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have earned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $14.8333.

Several brokerages have recently weighed in on KPTI. The Goldman Sachs Group set a $12.00 price target on Karyopharm Therapeutics in a research report on Wednesday, December 17th. Royal Bank Of Canada decreased their target price on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday, November 4th. Robert W. Baird cut their price target on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, October 9th. HC Wainwright raised shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Monday, October 13th. Finally, Piper Sandler reissued an “overweight” rating and set a $12.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th.

Karyopharm Therapeutics Price Performance

Shares of KPTI stock opened at $6.31 on Friday. The stock has a market capitalization of $115.54 million, a price-to-earnings ratio of -0.43 and a beta of 0.21. The company’s fifty day simple moving average is $6.55 and its two-hundred day simple moving average is $5.92. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $10.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($3.82) earnings per share for the quarter, missing the consensus estimate of ($3.30) by ($0.52). The firm had revenue of $44.04 million during the quarter, compared to the consensus estimate of $39.56 million. Equities research analysts anticipate that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Hedge funds have recently bought and sold shares of the stock. Baird Financial Group Inc. bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter worth $45,000. XTX Topco Ltd bought a new position in Karyopharm Therapeutics in the second quarter valued at $56,000. Bridgeway Capital Management LLC purchased a new stake in Karyopharm Therapeutics during the second quarter valued at about $163,000. ADAR1 Capital Management LLC purchased a new stake in Karyopharm Therapeutics during the third quarter valued at about $164,000. Finally, Silverback Asset Management LLC lifted its stake in Karyopharm Therapeutics by 40.0% during the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after purchasing an additional 20,000 shares during the last quarter. 66.44% of the stock is currently owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.